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Background: Alzheimer's disease (AD) is the most common form of dementia and 
causes a progressive and irreversible neurodegeneration. The loss of cholinergic 
neurons leads to the progressive reduction of acetylcholine (ACh) in the brain and 
resulting cognitive impairment in AD. ACh is hydrolyzed by both acetylcholinesterase 
(AChE) and butirylcholinesterase (BuChE). It was found that in the course of the 
disease, levels of AChE in the central nervous system (CNS) decrease, inversely to 
BuChE levels, so both enzymes represent legitimate therapeutic targets for ameliorating 
the cholinergic deficit characteristic of AD.  
Objective: Screen a library of new isoquinoline, indolinone and benzoazepinone 
derivatives for their ability to inhibit AChE and BuChE activities, using galantamine and 
rivastigmine as standards. 
Methods: The enzyme activities and inhibition studies were carried out using 
spectrophotometric techniques, based on the Ellman’s method, with acetylthiocholine 
(ATCI) and butirylthiocholine (BTCI) as substrates, for AChE and BuChE, respectively. 
The data were complemented with modeling to analyze the structure-activity 
relationship. 
Results: Our results show that the tested compounds are competitive inhibitors for 
AChEs and BuChEs, as the benchmarks galantamine and rivastigmine. The isoquinoline 
and indolinone derivative compounds showed strong anti-cholinesterases activities, with 
IC50 values ranging from 0.4 to 400 micromolar. 
Conclusions: The results presented are promising and provide a pathway for the design 
of new AChE and BuChE inhibitors. 
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